Business Wire

Relation Therapeutics announces launch of flagship integrated wet–dry laboratory at the heart of London’s Knowledge Quarter

22.2.2023 09:00:00 EET | Business Wire | Press release

Share

Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory. The laboratory and offices comprise 5,500 sq ft, located at the heart of London’s Knowledge Quarter, in close reach of collaborators and partners including globally renowned academic research centres and major pharma companies. Over the last year the company has grown to a 35-strong cross-disciplinary seed-stage company. The new space is another step forward in realising Relation’s ambition to establish a novel transformational approach to drug discovery.

The integrated wet–dry laboratory’s unique value for drug discovery comes from efficiently combining the most sophisticated functional genomic techniques with extraordinary computational power and machine learning. With the acquisition of genomic data from human cells, Relation obtains direct insights into critical biological relationships, which are then fed directly into the dry laboratory’s machine learning engine. The engine then automatically requests new experiments to improve its predictive ability, cutting through an otherwise undecipherable combinatorial space. This sequence of experiments is the essence of Relation’s Lab-in-the-Loop and by uniting these two technologies Relation aims to radically improve the probability of success of drug discovery and development.

“Deploying machine learning to understand such a vast array of interactions between genes, proteins and drugs holds extraordinary potential for discovering new drugs,” said Sir Paul Nurse, CEO of the Francis Crick Institute who alongside the executive team led the official opening. “It is pleasing to see Relation Therapeutics joining the Crick and other innovative bioscience enterprises in the Knowledge Quarter, further enhancing London’s already internationally distinguished bio ecosystem.”

Relation Therapeutics further announced the appointment of Dr. Edith M. Hessel, a former GSK R&D executive, as Chief Scientific Officer (CSO). Dr. Hessel will lead the drug discovery direction of the company and the progression of its pipeline to the clinic. Dr. Hessel has successfully pioneered the development of novel target discovery platforms, advanced therapeutics from inception to clinical proof of concept, and has extensive experience in founding biotech companies. As a VP at GSK, Dr. Hessel built the Refractory Respiratory Inflammation Discovery Performance Unit, which added multiple novel targets to GSK’s pipeline.

“I am absolutely delighted to be part of Relation’s mission to transform drug discovery, probing unexplored molecular target spaces for potentially life-changing medicines,” said Edith Hessel. “Relation combines a world-class team with cutting-edge technology, including access to NVIDIA’s Cambridge-1, the UK’s most powerful super-computer. Utilising first-class computational capacity to explore experimental data, clinical insights and high-resolution biology will transform drug discovery as we know it, allowing us to develop better medicines for patients.”

In addition, Relation shared their vision for indication selection, which uses a proprietary machine learning engine - SelectomaticTM - to recommend those indications where Relation’s integrated platform enables the development of transformational therapeutics. Application of this engine led to the initiation of osteoporosis as the first disease that Relation will pursue. Osteoporosis, a metabolic bone disease, is characterised by low bone density and deterioration of bone architecture, increasing the risk of fractures.1 It is estimated that there are approximately ten million people with osteoporosis in the USA alone,1 with nearly one million considered to be patients at high risk of fractures. Furthermore, in Europe, 32 million people over 50 are estimated to have osteoporosis.2 Current treatment options have a number of limitations, including safety concerns, low uptake, and limited duration of efficacy.

“The use of single-cell profiling allows our scientists to understand bone biology with exquisite detail and provides us with the unique opportunity to be at the forefront of finding a next-generation therapy for osteoporosis,” said Dr. David Roblin, Chief Executive Officer. “This access to rich single-cell data perfectly enables the power of our machine learning engine in a disease of significant unmet need.”

In their mission to discover life-changing medicines, the team at Relation Therapeutics leverages their extensive experience in building successful biotechnology businesses. This includes Dr. Charlie Roberts, the Chairperson of Relation, who is the co-founder of Freenome, a San Francisco-based company that has raised over $1bn from investors including Roche and Novartis. In June 2022, DCVC and Magnetic Ventures co-led a $25-million round of seed financing, with participation from Khosla Ventures, OMERS Ventures, and Firstminute Capital, among others.

To learn more about Relation Therapeutics, please visit: https://www.relationrx.com/.

About Relation

Relation is a biotechnology company focused on leveraging computational and experimental techniques to understand biology better. Central to Relation’s approach is its integrated wet–dry laboratory which leverages human genetics, single-cell profiling and machine learning to generate new insights with real translational validity. The company is located in London.

References

  1. Wright N, Looker A, Saag K, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526.
  2. Kanis JA, et al., SCOPE 2021: a New Scorecard for Osteoporosis in Europe, Arch Osteoporos, 2021, 16(1):82.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further queries, please contact:
Dr. Rosie Rodriguez – SVP, Growth, Relation Therapeutics: rosie@relationrx.com; +44 7511 183023

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 19:00:00 EET | Press release

WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 17:16:00 EET | Press release

Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release

Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release

Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release

Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye